CN101254223A - Pomegranate rind and novel method for improving prostate gland symptoms with carthaginian apple seed extract - Google Patents
Pomegranate rind and novel method for improving prostate gland symptoms with carthaginian apple seed extract Download PDFInfo
- Publication number
- CN101254223A CN101254223A CNA2008100265717A CN200810026571A CN101254223A CN 101254223 A CN101254223 A CN 101254223A CN A2008100265717 A CNA2008100265717 A CN A2008100265717A CN 200810026571 A CN200810026571 A CN 200810026571A CN 101254223 A CN101254223 A CN 101254223A
- Authority
- CN
- China
- Prior art keywords
- pericarpium granati
- prostate
- extract
- megranate seed
- seed
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention provides an extract from the peel and the seeds of Punica granatum. The extract can be used for preparing drugs as well as health food and food additives for treating hyperplasia of prostate and prostatitis. Experimental results on mice with hyperplasia of prostate show that the extract from the peel and the seeds of Punica granatum can effectively improve the prostate weight and prostate index, improve malondialdehyde (MDA) level and testosterone level in prostate, improve antioxidant ability in plasma, and regulate nitrogen oxide (NO) level in plasma. Also, the experimental results show that the extract from the peel and the seed of Punica granatum can improve the lecithin corpuscle density and leukocyte count in prostate, increase the activity of prostatic acid phosphatase (PACP), and regulate the MDA and NO levels in prostate. The in vitro experiments show that the extract from the peel and the seeds of Punica granatum has strong antioxidant effect. The extract from the peel and the seeds of Punica granatum has high safety and definite bioactivity. Therefore, the dose of the extract from peel and seed of Punica granatum in finished products of drugs, health food or food additives is 0.001-100 wt%.
Description
Technical field
The present invention relates to field of medicaments, specifically be natural plant extracts and application thereof, especially relate to the application that Punica granatum L. (Punicagranatum Linn.) skin and Megranate Seed P.E are used to prepare medicine, health food and the food additive of anti-prostatic hyperplasia and resistance prostatitis.
Background technology
Prostatic hyperplasia, be commonly called as prostate hyperplasia, be meant that owing to prostate parenchyma quantity increases the increase that causes prostate organs relate to the cell mitogen activity enhanced results that Different types of etiopathogenises causes, its feature shows as substrate and epithelial hypertrophy.Prostatic hyperplasia is one of elderly men commonly encountered diseases, generally begins outgrowth pathological change after 40 years old, occurs related symptoms after 50 years old.The sickness rate of hyperplasia of prostate increases progressively with age growth, but clinical symptoms is the most obvious with 60-70 year.The prostatic hyperplasia cardinal symptom has dysuria, frequent micturition, urinate initial slow, the urine line is unable, urine is interrupted or the sound of rain pattering etc., also acute urinary retention, urinary retention with overflow incontinence can take place what is more, had a strong impact on the quality of life of elderly men, even various complication appear, threaten patient's life, become one of most important disease that influences China's elderly men health.Mechanism that it is generally acknowledged prostatic hyperplasia and elderly men dihydrotestosterone gland intravital gather relevant.
Prostatitis is male urinary system frequently-occurring disease, commonly encountered diseases, and it is not single disease, and its cause of disease is organ constitutional or Secondary cases in a organized way, and is also relevant with infection and inflammation.Wherein, acute prostatitis mostly is infectious disease, is the clinical symptoms of feature and chronic prostatitis is considered as infecting or non-infective agent effect forms down with symptoms such as parurias.Because the non-infectious prostatitic cause of disease is also indeterminate, therefore can think that the factor that causes prostatitis is of a great variety, the mechanism of action complexity.People extremely pay close attention to the relation between inherited genetic factors, endocrine disturbance and aging etc. and prostatitis morbidity in recent years, the prostate battle-weary and that particular job causes that also noticing to load causes is congested for a long time, all may participate in or have influence on prostatitic generation directly.Also have a lot of researchs to think, the shortage of trace elements zn and body oxidative stress status also may be one of prostatitic pathogenesis to the damage of histoorgan.
At present the drug main of treatment prostatic hyperplasia will be divided into the 5 acceptor inhibitor, alpha 1 adrenergic receptor blocker, short corpus luteum releasing hormone class medicines such as antiandrogen class such as Flutamide and megestrol acetate.These medicines are subjected to certain limitation, also are confined to temporary alleviation more on effects on clinical using dosage, and can not fundamentally reach therapeutic purposes.In addition, the 5 inhibitor shows the side effect relevant with property clinically, the many side effect of alpha-blocking agent with the cardiovascular aspect, and expense is all.Antiandrogen class, short corpus luteum releasing hormone class drug side effect use greatly and seldom.Patients with chronic prostatitis uses antibacterials easily to cause dysbacteriosis immunity degradation in the body, and antibacterials can not reach effective treatment level in prostata tissue and acinus mostly.Studies have shown that up to now, inflammation, the generation of diseases such as tumor and aging and interior free yl produce too much or remove the free radical ability drop confidential relation.We are in medicine, health food, food and the food additive of being devoted to seek and develop new anti-prostatic hyperplasia and resistance prostatitis from the natural product of resistant activity oxygen-derived free radicals for this reason.We note and confirm the anti-prostatic hyperplasia and the resistance prostatitis action effect of Pericarpium Granati and Megranate Seed P.E under study for action, are intended to develop its using value.
Punica granatum L. (Punica granatum Linn.) belongs to the mature fruit of Punicaceae (Punicaceae) Punica (Punica) machaka or dungarunga plant, originate in the Balkan Peninsula to Iran and neighbouring area thereof, extensively plant in the global torrid zone and subtropical zone at present.China introduces a fine variety the with a long history and widely cultivation of Punica granatum L..In recent years, people are concerned about the research to the natural product physiologically active very much, and are noticeable especially to traditional Chinese herbal medicine and biological function that natural plant kind has.Modern medicine study thinks that Pericarpium Granati contains " pomegranate root skin alkali ", and various bacillus and its bacterium of skin are all had inhibitory action.Pericarpium Granati contains more tannin, and the convergence bactericidal effect is arranged, and can control diarrhoea, dysentery, and can whet the appetite, aid digestion.Pericarpium Granati is rich in multiple polyphenol compounds such as catechin, has very strong antioxidations such as the oxygen-derived free radicals of removing.Granada seed oil is rich in punicic acid, and very strong oxidation resistance is arranged, and can suppress the key enzyme of lipoxidase, Cycloxygenase and arachidonic acid pathway, the destruction of opposing human body inflammation and oxygen-derived free radicals.Pericarpium Granati and Megranate Seed P.E have certain antiinflammatory, antibiotic, antitumor action etc. to be familiar with by people, but does not still have the discussion of any application facet for Pericarpium Granati and Megranate Seed P.E anti-prostatic hyperplasia and resistance prostatitis.
Summary of the invention
The object of the present invention is to provide the new purposes of Pericarpium Granati and Megranate Seed P.E.
Of the present invention is raw material with Pericarpium Granati and Megranate Seed P.E, the medicine that is used to prepare anti-prostatic hyperplasia and resistance prostatitis and alleviates its clinical symptoms.Drug prepared can be taken for a long time, and is safe and have no side effect.
Pericarpium Granati of the present invention and Megranate Seed P.E are raw material, are used to the food and the food additive that prepare anti-prostatic hyperplasia and resistance prostatitis and alleviate its clinical symptoms.Prepared food and food additive can be taken for a long time, and be safe and have no side effect.In its application product, the use amount of described Pericarpium Granati and Megranate Seed P.E can account for 0.001～100% weight ratio.
Pericarpium Granati of the present invention and Megranate Seed P.E are to adopt one or more any mixed solvent of lower alcohols such as water or water and methanol, ethanol, acetone isopolarity solvent to extract.Because be rich in flavone, polyatomic phenol material and class nutritional labelings such as rich in amino acid, fatty acid, polysaccharide and trace element in Pericarpium Granati and the Megranate Seed P.E, high polar compound in all belonging to, the lower alcohols of general water or variable concentrations, acetone isopolarity solvent or any mixed solvent extract.When extracting, can suit to adjust the response rate that determining alcohol is used for improving Pericarpium Granati and Megranate Seed P.E active component.When extracting, can influence the content of active component in the extract because of the change of conditions such as temperature, method and time.But for extraction of active ingredients in Pericarpium Granati and the Megranate Seed P.E, said extracted method and combination in any thereof all can reach the recovery of extract of the present invention.
In view of Pericarpium Granati and Megranate Seed P.E are to develop as final products with medicine or health food and food additive, should select aquiferous ethanol to be advisable so consider to extract solvent from safety perspective as far as possible.The ratio of Pericarpium Granati and Semen Granati and solvent does not have specific limited during extraction, but considers that generally the ratio of Pericarpium Granati and Semen Granati and solvent is advisable with 1: 1～50 scopes.The present invention does not have specific limited to extracting temperature, and is all applicable to the solvent boiling point temperature from room temperature.Certainly room temperature, normal pressure and in the solvent boiling point scope, extract ideal.Extraction time can reach the recovery purpose of active component to a certain extent from 30 seconds to 24 hours.When extracting Pericarpium Granati extract and Megranate Seed P.E, also can in solvent, add materials such as sodium bicarbonate, SODIUM ASCORBATE as required.These extracting method can not influence the biological activity that Pericarpium Granati and Megranate Seed P.E had originally.
Pericarpium Granati provided by the invention and Megranate Seed P.E solid agent use amount are generally at 0.001% to 100% (W/W), and peroral dosage form interpolation concentration is generally comparatively suitable in 0.1% to 50% (W/W) scope usually.Along with the increase of addition, pained and oily sensation may appear as the Pericarpium Granati extract of food additive and Megranate Seed P.E.Its solution can require according to the psychology of market demand and consumer to change dosage form, for example uses dosage forms such as tablet, granule, capsule.
Pericarpium Granati provided by the invention and Megranate Seed P.E and active component thereof can be used for various peroral dosage forms and put on market, are used for anti-prostatic hyperplasia and resistance prostatitis and alleviate its clinical symptoms.Certainly, Pericarpium Granati and Megranate Seed P.E also can combine with pharmaceutical carriers such as excipient commonly used and make preparation.In case of necessity, can also add preparation additives such as some antiseptic, antioxidant, pigment, sweeting agent.Relatively Shi Yi Pericarpium Granati and Megranate Seed P.E excipient generally consider to have lactose, sucrose, mannitol, starch, crystalline cellulose etc.Lubricant generally should adopt magnesium stearate, calcium stearate, Pulvis Talci etc.Solvent uses Purified Water, ethanol, propylene glycol etc. usually.Antiseptic generally adopts methaform, benzylalcohol, dihydroxy acetic acid etc.Antioxidant is more suitable with sulphite, ascorbic acid etc. usually.
Pericarpium Granati provided by the invention and Megranate Seed P.E, its solution or powder can be added to be used in the goods oral.Pericarpium Granati and Megranate Seed P.E also can combine with the Other Drinks raw material and make certain beverage product, as Pericarpium Granati and Megranate Seed P.E beverage, soda pop, fruit drink, lactobacillus beverage, sports drink, soyabean milk etc.Pericarpium Granati and Megranate Seed P.E it is also conceivable that daily breads such as making cookies, chocolate, confection, chewing gum, snack, fruit jelly dessert, bread, bean curd, yoghourt.
Pericarpium Granati provided by the invention and Megranate Seed P.E and contained active component thereof can be used as medicine, health food, food or food additive, are used for anti-prostatic hyperplasia and resistance prostatitis and alleviate its clinical symptoms.Among the present invention, the dosage of Pericarpium Granati and Megranate Seed P.E can suitably be selected according to the conditions such as relative health status, age, sex and body weight of user.Adult's average weight is with 60 kilograms of calculating, and one day oral Pericarpium Granati and Megranate Seed P.E generally can be considered at 1 gram to 5 gram scopes, part vic.There are not problems such as side effect more than certain 5 grams yet.
The present invention causes the mice prostatic hyperplasia as the prostatic hyperplasia experimental model with the subcutaneous injection Testosterone Propionate, cause the rat prostate inflammation as the nonbacterial prostatitis model with injection carrageenin in the prostate, cause the rat prostate inflammation as the bacterial prostatitis model with injection staphylococcus aureus in the prostate, estimate Pericarpium Granati and Megranate Seed P.E to prostatic hyperplasia mouse model weight of prostate and prostate index, the level of serum testosterone (testosterone), (the oxygenradical absorbance capacity of ORAC in the blood plasma, ORAC), malonaldehyde (malondialdehyde in the prostate, MDA) level, the influence of plasma nitric oxide (NO) level.Estimate Pericarpium Granati extract and Megranate Seed P.E prostate lecithin density and leukocyte count to the prostatitis rat, the vigor of acid phosphatase in the blood plasma (PACP), the influence of malonaldehyde in the prostate (MDA), NO level, Zn content and ORAC ORAC.The result shows that Pericarpium Granati and Megranate Seed P.E are to mice prostatic hyperplasia and the effect of being significantly improved of rat prostate inflammation.
Can prove according to above-mentioned experiment and the invention provides Pericarpium Granati and Megranate Seed P.E is a kind of safe, natural medicine, food and food additive, by effects such as NO in antioxidation, the control agent, thereby reach the purpose of anti-prostatic hyperplasia and resistance prostatitis.
In addition, the present invention also points out Pericarpium Granati and Megranate Seed P.E also to can be used as antioxidant or antioxidation constituent raw material, is used for alleviating and improves by the reaction that causes inflammation such as prostatic hyperplasia and prostatitis.Because Pericarpium Granati provided by the invention and Megranate Seed P.E are the materials of natural origin, and among the peoplely have a long-term edible experience, be applicable to the crowd of each age level and health status.Therefore, Pericarpium Granati and Megranate Seed P.E can be used as health food, food additive and multiple use are provided.Though Pericarpium Granati and Megranate Seed P.E antiinflammatory action are known, anti-prostatic hyperplasia that Pericarpium Granati and Megranate Seed P.E demonstrate and prostatitis activity are that the present invention confirms first.
The specific embodiment:
The present invention can be elaborated by following examples, but is not limited only to following examples.
Embodiment one: the preparation of Pericarpium Granati extract
Get the Pericarpium Granati of fresh dried, pulverize the back fully and added 80 ℃ of heating and refluxing extraction of 10 times of amount 70% ethanol 3 hours, extract altogether 3 times, filter the back merging filtrate, 45 ℃ of concentrating under reduced pressure postlyophilizations promptly get the response rate and are about 42.34% Pericarpium Granati extract and are used for the following example of the present invention.
Embodiment two: the preparation of Megranate Seed P.E
Get dry Semen Granati coarse powder,, extract altogether 3 times, filter the back merging filtrate, promptly get the response rate behind 45 ℃ of concentrating under reduced pressure and be about 14.54% Megranate Seed P.E and be used for the following example of the present invention with 5 times of amount acetone 60 ℃ of heating and refluxing extraction 3 hours.
Embodiment three: Pericarpium Granati and Megranate Seed P.E are to external inhibitory action to the 5-alpha-reductase
The extract 6mg/ml of Testosterone Propionate 30 μ M, NADPH30 μ M, enzyme, the abundant sample that mixes the variable concentrations of back adding embodiment one and two preparations, 37 ° were reacted 10 minutes, and testing conditions is the 340nm wavelength.Select 15 μ g/ml finasteride groups to organize in contrast and estimate Pericarpium Granati and the relative inhibitory action of Megranate Seed P.E to enzymatic activity, (seeing accompanying drawing 1,2)
Embodiment four: Pericarpium Granati and Megranate Seed P.E cause the influence of prostatic hyperplasia mice prostate weight in wet base and prostate index (PI) to testosterone
Mice is divided into blank group, testosterone at random brings out prostatic hyperplasia model matched group, positive drug proscar group (19.47mg/kg), Pericarpium Granati extract low dose group (250mg/kg), Pericarpium Granati extract high dose group (500mg/kg), Megranate Seed P.E low dose group (food-intake 0.12%), Megranate Seed P.E high dose group (food-intake 1.2%), every group of 10 mices.Respectively organize mice subcutaneous injection every day with the dissolved Testosterone Propionate of olive oil (7.5mg/kg) beyond the blank group, injected continuously 12 days, simultaneously gastric infusion.Blank and model group gives the aqueous solution with capacity, and empty stomach is 24 hours after the last administration, and etherization is peeled off prostate, weighs, and calculates prostate weight in wet base and prostate index (PI).The experimental result experimental data is represented with x ± s, adopts Student t-test check to do statistical procedures.The result shows that compare with normal control group mice, testosterone brings out prostatic hyperplasia model mice prostate weight in wet base and PI all has remarkable increase (P＜0.01).Compare with the prostatic hyperplasia model group, proscar group, the high low dose group of Pericarpium Granati extract, the high low dose group mice of Megranate Seed P.E prostate weight in wet base and prostate index all have remarkable decline (P＜0.05 or P＜0.01), and are dose-effect relationship (table 1) with drug level.
Table 1 Pericarpium Granati and Megranate Seed P.E cause prostatic hyperplasia mice prostate weight in wet base and the exponential influence of prostate to testosterone
##P＜0.01 is compared with the blank group;
*P＜0.05,
*P＜0.01 is compared with the testosterone model control group and to be had statistical significance.
Embodiment five: Pericarpium Granati and Megranate Seed P.E cause the influence of prostatic hyperplasia mice prostata tissue malonaldehyde (MDA) level to testosterone
Laboratory animal, experimental technique, experiment grouping and dosage are all identical with embodiment four.Get the prostata tissue sample, make 10% prostata tissue homogenate, get the tissue homogenate supernatant after centrifugal 10 minutes for 10000 rev/mins and measure wherein mda content with normal saline.Measuring principle utilize malonaldehyde to contract with thiobarbituricacid (TBA) and, form red product, use microplate reader (Finland's thunder win the MK3 microplate reader) mensuration down at 532nm.Compare with normal control group mice, malonaldehyde (MDA) level in the homogenate of prostatic hyperplasia model mice prostata tissue significantly raise (P＜0.01), compare with the prostatic hyperplasia model group, proscar group, the high low dose group of Pericarpium Granati extract, the high low dose group of Megranate Seed P.E can obviously reduce malonaldehyde (MDA) level (P＜0.05 or P＜0.01) in the homogenate of mice prostata tissue, and the decline of Pericarpium Granati extract group and drug level are dose-effect relationship (table 2).
Table 2 Pericarpium Granati and Megranate Seed P.E cause the influence of prostatic hyperplasia mice prostate MDA level to testosterone
##P＜0.01 is compared with the blank group;
*P＜0.05,
*P＜0.01 is compared with the testosterone model control group and to be had statistical significance.
Embodiment six: Pericarpium Granati and Megranate Seed P.E cause the influence of prostatic hyperplasia mice serum testosterone to testosterone
Laboratory animal, experimental technique, experiment grouping and dosage are all identical with embodiment four.Mice heart blood sampling under the etherization condition, and place centrifuge tube that heparin handled with centrifugal 5 minutes separated plasmas of 5000rpm.Radioimmunoassay is measured the level of mice serum testosterone.Experimental result proves, with normal control group mice, testosterone causes prostatic hyperplasia mice serum testosterone levels significantly raise (P＜0.01).Testosterone causes prostatic hyperplasia model group mice and compares, and proscar group, the high low dose group of Pericarpium Granati extract, the high low dose group of Megranate Seed P.E all can obviously reduce mice serum testosterone levels (P＜0.01), and is dose-effect relationship (table 3) with drug level.
Table 3 Pericarpium Granati and Megranate Seed P.E cause the influence of prostatic hyperplasia mice serum testosterone levels to testosterone
##P＜0.01 is compared with the blank group;
*P＜0.01 is compared with the testosterone model control group and to be had statistical significance.
Embodiment seven: Pericarpium Granati and Megranate Seed P.E cause the influence of prostatic hyperplasia mice plasma ORAC (ORAC) to testosterone
Laboratory animal, experimental technique, experiment grouping and dosage are all identical with embodiment four.Mice is being put into the centrifuge tube that heparin was handled after heart blood sampling under the etherization condition, through 5000 rev/mins of separated plasmas after centrifugal 5 minutes.After 3% perchloric acid removed albumen, 12000 rev/mins of centrifugal 15 minutes recovery supernatant were used for ORAC and analyze.Blood plasma ORAC (ORAC) analysis is used multi-functional fluorescence analyser (Tecan Genios, Austria), excite with emission wavelength and be respectively 485nm and 525nm, the oxidant of attacking fluorescein (disodium fluorescein) uses 2,2 '-azobis-2-amidinopropane-dihydrochloride (AAPH; Wako Pure Chemical Industries, Ltd.Osaka, Japan).Experimental result is done statistical procedures with the t check, with normal control group mice, the blood plasma ORAC that testosterone causes the prostatic hyperplasia mice significantly reduces, (P＜0.05), causing prostatic hyperplasia model group mice with testosterone compares, can the raise blood plasma ORAC of mice of proscar group, the high low dose group of Pericarpium Granati extract, the high low dose group of Megranate Seed P.E, promptly the ability of resistant activity oxygen-derived free radicals obviously strengthens (P＜0.01), and has certain dose-effect relationship (table 4).
Table 4 Pericarpium Granati and Megranate Seed P.E cause the influence of prostatic hyperplasia mice plasma ORAC (ORAC) to testosterone
#P＜0.05 is compared with the blank group;
*P＜0.01 is compared with the testosterone model control group and to be had statistical significance.
Embodiment eight: Pericarpium Granati and Megranate Seed P.E cause the influence of nitric oxide in the prostatic hyperplasia mice plasma (NO) level to testosterone
Laboratory animal, experimental technique, experiment grouping and dosage are all identical with embodiment four.Nitric oxide (NO) is as the extremely strong free radical of a kind of reactivity in the organism, have oxidation and antioxidative dual function, have the effect of second message,second messenger and neurotransmitter concurrently, be again a kind of effector molecule simultaneously, multiple pathology, physiological process such as inflammatory reaction, cellulotoxic effect and immunologic injury are regulated in mediation.Adopt the Griess method, utilize 1% p-anilinesulfonic acid., 0.1%N-(1-naphthyl)-ethylenediamine, 5% phosphoric acid carry out diazonium, azo reaction, generate red product, in the colorimetric determination of 550nm place, make standard with sodium nitrite, are converted into NO at last
3-Concentration.Experimental result proves, compare with normal control group mice, testosterone causes prostatic hyperplasia mice plasma NO level significantly raise (P＜0.01), causing prostatic hyperplasia model group mice with testosterone compares, proscar group, the high low dose group of Pericarpium Granati extract, the high low dose group of Megranate Seed P.E can obviously reduce mice plasma NO level (P＜0.05), and have certain dose-effect relationship (table 5).
Table 5 Pericarpium Granati and Megranate Seed P.E cause the influence of prostatic hyperplasia mice plasma NO level to testosterone
#P＜0.05 is compared with the blank group;
*P＜0.05 is compared with the testosterone model control group and to be had statistical significance.
Embodiment nine: Pericarpium Granati and Megranate Seed P.E are to the influence of prostatitis rat model lecithin density and leukocyte count
Rat is divided into blank group, prostatitis model control group, positive drug QIANLIEKANG group (500mg/kg), Pericarpium Granati extract low dose group (250mg/kg), Pericarpium Granati extract high dose group (500mg/kg), Megranate Seed P.E group (food-intake 0.12%) at random, Megranate Seed P.E group (food-intake 1.2%), every group of 8 rats.The first gastric infusion of respectively organizing beyond the blank group perform the operation after 7 days, got 1% carrageenin that 0.2ml is made into distilled water and directly injected prostate dorsal part leaf, and peritoneal suture and skin prepare the nonbacterial prostatitis model then.Continue administration 3 days, the last administration is etherization after 40 minutes, carefully separates each leaf prostate, takes by weighing weight of prostate with electronic balance, adds physiological saline solution by 4ul/mg, homogenate, microscopically record lecithin density and leukocyte count.Bacterial prostatitis model preparation, get 0.2ml with normal saline be made into 10
7Individual/ml staphylococcus aureus is directly injected prostate dorsal part leaf and duplicates the bacterial prostatitis model, and experimental technique, experiment grouping are all with above-mentioned nonbacterial prostatitis model.Experimental data represents that with x ± s experimental result adopts the Studentt-test check to do statistical procedures.
Lecithin and leukocyte are two main aspects in the examination of prostatic fluid.When prostate was inflamed pathological changes, macrophage was engulfed lecithin in a large number, and leukocyte count increases simultaneously.Therefore write down lecithin density and leukocyte count has important value to the diagnosis of prostate inflammation.Experimental result proves, compare with rats in normal control group, prostatitis rat model prostate lecithin density all has remarkable decline (P＜0.01), leukocyte count significantly increases (P＜0.01), compare greatly with the prostatitis model group, QIANLIEKANG group, the high low dose group of Pericarpium Granati extract, the high low dose group rat prostate of Megranate Seed P.E lecithin density all have remarkable rising (P＜0.01), leukocyte count significantly reduces (P＜0.01), and has certain dose-effect relationship (table 6).
Table 6 Pericarpium Granati and Megranate Seed P.E are to the influence of prostatitis rat model lecithin density and leukocyte count
##P＜0.01 is compared with the blank group;
*P＜0.05,
*P＜0.01 is compared with the prostatitis model control group and to be had statistical significance
Embodiment ten: Pericarpium Granati and Megranate Seed P.E are to the influence of prostatitis rat model phosphatase acid serum vigor
Laboratory animal, experimental technique, experiment grouping and dosage are all identical with embodiment nine.After the last administration 40 minutes, rat heart blood sampling and leaving standstill 1 hour under the etherization condition, then, under 4 ℃ of conditions with centrifugal 15 minutes separation of serum of 3000rpm and measure prostate acid phosphatase activity in the serum.The active prostate acid phosphatase testing cassete that uses of prostatic fraction of serum acid phosphatase is measured.Measuring principle is that prostate acid phosphatase produces alpha-Naphthol and inorganic phosphate by the hydrolysis of catalysis alpha-Naphthol phosphate, the reaction of alpha-Naphthol and diazol generates coloured azo-compound, in the colorimetric determination of 530nm place and calculate the activity of prostate acid phosphatase.Experimental result with 1L serum under 37 ℃ of conditions with substrate-function, the free phenol that per minute produces 1 μ mol is an active unit.Experimental result proves, compares with rats in normal control group, and prostatitis rat acid phosphatase all has remarkable rising (P＜0.01).Compare with prostatitis rat model group, QIANLIEKANG group, the high low dose group of Pericarpium Granati extract, the high low dose group rat plasma of Megranate Seed P.E acid phosphatase enzyme activity all have reduction (P＜0.05) in various degree, and have certain dose-effect relationship (table 7).
Table 7 Pericarpium Granati and Megranate Seed P.E are to the influence of prostatitis rat model phosphatase acid serum vigor
##P＜0.01 is compared with the blank group;
*P＜0.05 is compared with the prostatitis model control group and to be had statistical significance
Embodiment 11: Pericarpium Granati and Megranate Seed P.E are to the influence of prostatitis rat model prostata tissue MDA level
Laboratory animal, experimental technique, experiment grouping and dosage are all identical with embodiment nine.Experimental result proves, compares with rats in normal control group, and the prostatitis rat prostate organizes the MDA level that remarkable rising (P＜0.05) is all arranged.Compare with prostatitis model group rat, QIANLIEKANG group, the high low dose group of Pericarpium Granati extract, the high low dose group rat prostate of Megranate Seed P.E organize the MDA level that remarkable reduction (P＜0.05 or P＜0.01) is all arranged, and have certain dose-effect relationship (table 8).
Table 8 Pericarpium Granati and Megranate Seed P.E are to the influence of prostatitis rat model prostata tissue MDA level
#P＜0.05 is compared with the blank group;
*P＜0.05,
*P＜0.01 is compared with the prostatitis model control group and to be had statistical significance
Embodiment 12: Pericarpium Granati and Megranate Seed P.E are to the influence of NO level in the prostatitis rat prostate tissue
Laboratory animal, experimental technique, experiment grouping and dosage are all identical with embodiment nine.Experimental result proves, compare with rats in normal control group, NO level significantly raise (P＜0.01) in the nonbacterial prostatitis rat model prostata tissue, compare with nonbacterial prostatitis model group rat, QIANLIEKANG group, the high low dose group of Pericarpium Granati extract, the high low dose group rat prostate of Megranate Seed P.E organize the NO level that remarkable reduction (P＜0.05 or P＜0.01) is all arranged.In addition, compare with rats in normal control group, the NO level significantly reduces (P＜0.05) in the bacterial prostatitis rat model prostata tissue, compare with bacterial prostatitis model group rat, the NO level all has remarkable rising (P＜0.05 or P＜0.01) in QIANLIEKANG group, the high low dose group of Pericarpium Granati extract, the high low dose group rat prostate of the Megranate Seed P.E tissue, and has certain dose-effect relationship (table 9).
Table 9 Pericarpium Granati and Megranate Seed P.E are to the influence of NO level in the prostatitis rat prostate tissue
##P＜0.01 is compared with the blank group;
*P＜0.05,
*P＜0.01 is compared with the prostatitis model control group and to be had statistical significance
Embodiment 13: Pericarpium Granati and Megranate Seed P.E are to the influence of middle zinc (Zn) content in the prostatitis rat prostate tissue
Laboratory animal, experimental technique, experiment grouping and dosage are all identical with embodiment nine.Experimental technique is with shears prostata tissue to be shredded, and is placed in the ice bath by every 100mg/mL interpolation normal saline and makes 10% homogenate with tissue refiner.Homogenate under 4 ℃ of conditions with 3000rpm behind the centrifugal 10min, get the homogenate supernatant with 50 times of distilled water dilutings after, use the TAS-990 atomic absorption spectrophotometer to detect and adopt standard curve method to calculate Zn content in the prostata tissue homogenate.Experimental result proves, compare with rats in normal control group, the content of Zn significantly reduces (P＜0.01) in the prostatitis rat prostate tissue, compare with prostatitis model group rat, QIANLIEKANG group, the high low dose group of Pericarpium Granati extract, the high low dose group of Megranate Seed P.E, rat prostate organize the content of Zn that remarkable rising (P＜0.05 or P＜0.01) is all arranged, and have certain dose-effect relationship (table 10).
Table 10 Pericarpium Granati and Megranate Seed P.E are to the influence of zinc (Zn) content in the prostatitis rat prostate tissue.
##P＜0.01 is compared with the blank group;
*P＜0.05 is compared with the prostatitis model control group and to be had statistical significance
Embodiment 14: Pericarpium Granati and Megranate Seed P.E are to the influence of ORAC (ORAC) in the prostatitis rat prostate tissue
Laboratory animal, experimental technique, experiment grouping and dosage are all identical with embodiment nine.Experimental result proves, compares with rats in normal control group, and ORAC significantly reduces (P＜0.01) in the prostatitis rat prostate tissue.Compare with prostatitis model group rat, QIANLIEKANG group, the high low dose group of Pericarpium Granati extract, the high low dose group rat prostate of Megranate Seed P.E organize ORAC that remarkable rising (P＜0.05 or P＜0.01) is all arranged, and have certain dose-effect relationship (table 11).
Table 11 Pericarpium Granati and Megranate Seed P.E are organized the influence of ORAC (ORAC) to the prostatitis rat prostate
##P＜0.01 is compared with the blank group;
*P＜0.05,
*P＜0.01 is compared with the prostatitis model control group and to be had statistical significance
Embodiment 15: the activity of the antioxidation in vitro Capability index (ORAC) of Pericarpium Granati and Megranate Seed P.E
Antioxidation in vitro experiment is that Pericarpium Granati and the Megranate Seed P.E with variable concentrations directly is added in the 96 hole ELISA Plate, and observation sample inhibited oxidation agent AAPH is to the delay action of the fluorescence decay of fluorescein (disodium fluorescein).As shown in Figure 3, Pericarpium Granati and Megranate Seed P.E by the speed of reactive oxygen free radical cancellation, have the effect of resistant activity oxygen-derived free radicals at the external fluorescent material that all can delay.The resistant activity oxygen-derived free radicals effect of Pericarpium Granati and Megranate Seed P.E may come from the punicic acid in micromolecule polyphenol compound and the Megranate Seed P.E.
The present invention brings out the mice prostatic hyperplasia with the subcutaneous injection Testosterone Propionate and causes the rat prostate inflammation as injection carrageenin in prostatic hyperplasia experimental model, the prostate and cause the rat prostate inflammation as the bacterial prostatitis model as injection staphylococcus aureus in nonbacterial prostatitis model and the prostate, estimates Pericarpium Granati and Megranate Seed P.E anti-prostatic hyperplasia and resistance prostatitis effect.The result shows the Pericarpium Granati of various dose and the MDA level that Megranate Seed P.E can effectively reduce prostata tissue homogenate, improves the oxidation resistance of body, regulates the NO level.Therefore can infer that Pericarpium Granati and Megranate Seed P.E can alleviate and improve the effects such as injury of prostate that prostatic hyperplasia and prostatitis cause, its effect may be to pass through antioxidation, prevent peroxide injury, the links such as generation of minimizing lipid peroxide realize.In addition, the present invention also points out Pericarpium Granati and Megranate Seed P.E to can be used as antioxidant or antioxidation constituent raw material, is used for some because the prevention and the auxiliary treatment of the disease that oxidative stress causes.Based on The above results, confirm the establishment of the new purposes of Pericarpium Granati of the present invention and Megranate Seed P.E.
According to above-mentioned experiment can prove the invention provides with Pericarpium Granati and Megranate Seed P.E be a kind of safety natural pass through antioxidation, thereby reach antiinflammatory action, alleviate and prevention, improvement and treatment prostatic hyperplasia and prostatitis, be used to prepare medicine that can take for a long time, safe without toxic side effect, food additive, health food and constituent thereof.Owing to the invention provides Pericarpium Granati and Megranate Seed P.E is the material of natural origin, and among the people secular edible experience arranged, be not only applicable to general adult, also be applicable to the low person of old people, child and muscle power.Therefore, with Pericarpium Granati and Megranate Seed P.E can be used as health food, food additive provides multiple use.Can prove that according to above-mentioned experiment Pericarpium Granati provided by the invention and Megranate Seed P.E are a kind of safe medicine, food and food additive.
Description of drawings
The external inhibitory action to the 5-alpha-reductase of Fig. 1 Pericarpium Granati extract: abscissa is Pericarpium Granati extract concentration (mg/ml), and experimental data represents that with x ± s vertical coordinate is relative inhibition (%).
The external inhibitory action to the 5-alpha-reductase of Fig. 2 Megranate Seed P.E: abscissa is Megranate Seed P.E concentration (mg/ml), and experimental data represents that with x ± s vertical coordinate is relative inhibition (%).
The activity of the antioxidation in vitro Capability index (ORAC) of Fig. 3 Pericarpium Granati and Megranate Seed P.E: abscissa be the time (minute), vertical coordinate is a relative intensity of fluorescence.Its principle be fluorescein sodium under the 485nm optical excitation, emission 527nm fluorescence, the peroxy radical oxidation that can be discharged by AAPH and fluorescent characteristic is disappeared.When antioxidant exists, can with fluorescein sodium competitive oxidation agent, slow down the speed that its fluorescence disappears.Contrast (the fluorescence decline curve when AAPH) expression does not add free-radical generating agent AAPH; Contrast (AAPH) expression adds free-radical generating agent AAPH, but the fluorescence decline curve when not adding sample; Other two curves are respectively: after adding free-radical generating agent AAPH, and the fluorescence decline curve when adding sample 0.25mg/ml Pericarpium Granati extract and 0.25mg/ml Megranate Seed P.E more respectively.
Claims (7)
1, is that effective ingredient is used to prepare anti-prostatic hyperplasia, resistance prostatitis with Pericarpium Granati and Megranate Seed P.E, alleviates and improve the purposes of the medicine of its clinical symptoms.
2, be that effective ingredient is used to prepare anti-prostatic hyperplasia, resistance prostatitis with Pericarpium Granati and Megranate Seed P.E, alleviate and improve the health food of its clinical symptoms and the purposes of food additive.
3, purposes according to claim 1 and 2, it is characterized in that: described Pericarpium Granati extract contains polysaccharide and polyphenol active ingredient and granada seed oil and contains the unsaturated fatty acids active component, and the content that polysaccharide and polyphenol active ingredient and granada seed oil contain the unsaturated fatty acids active component in every gram Pericarpium Granati extract is 5 milligrams of whats much.
4, purposes according to claim 1 and 2, it is characterized in that: described Pericarpium Granati and Megranate Seed P.E are to adopt one or more any mixed solvent of water or water and lower alcohols, polar solvent to extract, and also can add an amount of acid in solvent or alkali extracts.
5, purposes according to claim 1 is characterized in that: described medicine comprises the Pericarpium Granati and the Megranate Seed P.E of dose therapeutically effective, and pharmaceutically acceptable carrier.
6, purposes according to claim 1 and 2 is characterized in that: described Pericarpium Granati and Megranate Seed P.E use amount in the various preparation finished products of medicine or health food or food additive can account for 0.001～100% weight ratio.
7, purposes according to claim 4 is characterized in that: described Pericarpium Granati and Megranate Seed P.E can add sodium bicarbonate and/or SODIUM ASCORBATE in solvent when extracting.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2008100265717A CN101254223A (en) | 2008-03-04 | 2008-03-04 | Pomegranate rind and novel method for improving prostate gland symptoms with carthaginian apple seed extract |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2008100265717A CN101254223A (en) | 2008-03-04 | 2008-03-04 | Pomegranate rind and novel method for improving prostate gland symptoms with carthaginian apple seed extract |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101254223A true CN101254223A (en) | 2008-09-03 |
Family
ID=39889546
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2008100265717A Pending CN101254223A (en) | 2008-03-04 | 2008-03-04 | Pomegranate rind and novel method for improving prostate gland symptoms with carthaginian apple seed extract |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101254223A (en) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101991619A (en) * | 2009-08-10 | 2011-03-30 | 杭州赛利药物研究所有限公司 | Pomegranate controlled-release pellets and preparation method thereof |
| CN103442594A (en) * | 2010-12-23 | 2013-12-11 | 阿马曾提斯公司 | Compositions and methods for improving mitochondrial function and treating neurodenegenerative diseases and cognitive disorders |
| CN104116131A (en) * | 2014-07-16 | 2014-10-29 | 湖南中烟工业有限责任公司 | Pomegranate concentrate preparing method and application |
| CN104738446A (en) * | 2013-12-27 | 2015-07-01 | 大连中超食品有限公司 | Preparing methods of red raspberry seed extract product and red raspberry polymerization fruit juice and applications thereof |
| CN105123914A (en) * | 2015-09-25 | 2015-12-09 | 安徽民祯生物工程有限公司 | Clean vegetable natural preservative |
| KR20160059028A (en) * | 2014-11-17 | 2016-05-26 | 한국식품연구원 | Composition for Prevention, Treatment or Reduction of Prostate Hyperplasia Comprising Punicalagin |
| JP2021074000A (en) * | 2021-01-08 | 2021-05-20 | 小林製薬株式会社 | Composition for inhibiting phosphodiesterase-5 activity |
-
2008
- 2008-03-04 CN CNA2008100265717A patent/CN101254223A/en active Pending
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101991619A (en) * | 2009-08-10 | 2011-03-30 | 杭州赛利药物研究所有限公司 | Pomegranate controlled-release pellets and preparation method thereof |
| CN103442594A (en) * | 2010-12-23 | 2013-12-11 | 阿马曾提斯公司 | Compositions and methods for improving mitochondrial function and treating neurodenegenerative diseases and cognitive disorders |
| CN103442594B (en) * | 2010-12-23 | 2016-02-17 | 阿马曾提斯公司 | For improving composition and the method for mitochondrial function and treatment neurodegenerative disease and cognitive disorder |
| CN104738446A (en) * | 2013-12-27 | 2015-07-01 | 大连中超食品有限公司 | Preparing methods of red raspberry seed extract product and red raspberry polymerization fruit juice and applications thereof |
| CN104116131A (en) * | 2014-07-16 | 2014-10-29 | 湖南中烟工业有限责任公司 | Pomegranate concentrate preparing method and application |
| CN104116131B (en) * | 2014-07-16 | 2016-06-29 | 湖南中烟工业有限责任公司 | The application of Punica granatum L. concentrate |
| KR20160059028A (en) * | 2014-11-17 | 2016-05-26 | 한국식품연구원 | Composition for Prevention, Treatment or Reduction of Prostate Hyperplasia Comprising Punicalagin |
| KR101714370B1 (en) | 2014-11-17 | 2017-03-10 | 한국식품연구원 | Composition for Prevention, Treatment or Reduction of Prostate Hyperplasia Comprising Punicalagin |
| CN105123914A (en) * | 2015-09-25 | 2015-12-09 | 安徽民祯生物工程有限公司 | Clean vegetable natural preservative |
| JP2021074000A (en) * | 2021-01-08 | 2021-05-20 | 小林製薬株式会社 | Composition for inhibiting phosphodiesterase-5 activity |
| JP7237998B2 (en) | 2021-01-08 | 2023-03-13 | 小林製薬株式会社 | Composition for inhibiting phosphodiesterase 5 activity |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Jiang et al. | Effects of the ethanol extract of black mulberry (Morus nigra L.) fruit on experimental atherosclerosis in rats | |
| CN101254223A (en) | Pomegranate rind and novel method for improving prostate gland symptoms with carthaginian apple seed extract | |
| KR101965061B1 (en) | Composition for prevention or treatment of metabolic disorder comprising peanut sprout extracts and fractions thereof | |
| EP1700604A1 (en) | Alga extract and sugar hydrolase inhibitor containing the same | |
| EP1854470A1 (en) | Method of treating inflammation disorders using extracts of passion fruit | |
| KR101517833B1 (en) | A composotion for the treatment of dyslipidemia comprising the red ginseng complex | |
| Okokon et al. | Antiplasmodial and antidiabetic activities of ethanolic leaf extract of Heinsia crinata | |
| KR20140137289A (en) | Composition comprising an extract of Alpinia officinarum Hance for preventing and treating hangover or liver disease | |
| EP1369123A1 (en) | A health-care product comprising lotus rhizome and process for its preparation | |
| US20070053929A1 (en) | Marine algae extract and lipase inhibitor containing the same | |
| JP3662248B2 (en) | Immunostimulator | |
| KR101517836B1 (en) | A composition for the treatment of atherosclerosis comprising the red ginseng complex | |
| JP2009125030A (en) | Health food and drink, and medicine | |
| KR20140137288A (en) | Composition comprising an extract of Alpinia officinarum Hance for preventing and treating hangover or liver disease | |
| CN101646428A (en) | Be used for the treatment of or prevent diabetes comprise medical composition and its use from the alkannin derivant of Radix Arnebiae (Radix Lithospermi) | |
| Handayani et al. | Kecombrang (Etlingera elatior) Leaves Ethanol Extract Effect to Lens and Erythrocyte Aldose Reductase Activity in Wistar strain white rats (Rattus norvegicus) Streptozotocin induced | |
| KR101399398B1 (en) | Method for manufacturing submerged-state fermented Allium victorialis and Composition for preventing or treating anti-diabetes or anti-diabetic complication containing fermented Allium victorialis | |
| Mustafa et al. | Effect of acid load (citric acid) on diabetes-induced rats | |
| KR20200115927A (en) | Composition containing grape leaf extract and centella asiatica extract for improvement of venous circulation disorder | |
| CN108391815A (en) | A kind of ease constipation Weight reducing compound and preparation method | |
| KR102183687B1 (en) | Extract of Polygonatum odoratum for preventing non-alcoholic fatty liver | |
| JP6770726B1 (en) | Preventive or ameliorating agents for metabolic syndrome | |
| KR101351406B1 (en) | A composition for athero-sclerosis comprising the polyphenol extracts from Phellinus baumii | |
| US7687089B2 (en) | Extracts of passion fruit and uses thereof | |
| US7691423B2 (en) | Method of treating inflammation disorders using extracts of passion fruit |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| DD01 | Delivery of document by public notice |
Addressee: Feng Jinhe Document name: Notification that Application Deemed to be Withdrawn |
|
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Open date: 20080903 |